Approaching sites of action of temozolomide for pharmacological and clinical studies in glioblastoma
Temozolomide (TMZ), together with bulk resection and focal radiotherapy, is currently a standard of care for glioblastoma. Absorption, distribution, metabolism, and excretion (ADME) parameters, together with the mode of action of TMZ, make its biochemical and biological action difficult to understan...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2022
|
| In: |
Biomedicines
Year: 2022, Jahrgang: 10, Heft: 1, Pages: 1-27 |
| ISSN: | 2227-9059 |
| DOI: | 10.3390/biomedicines10010001 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/biomedicines10010001 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2227-9059/10/1/1 
|
| Verfasserangaben: | Margaux Fresnais, Sevin Turcan, Dirk Theile, Johannes Ungermann, Yasmin Abou Zeed, Joshua Raoul Lindner, Marius Breitkopf, Jürgen Burhenne, Walter E. Haefeli and Rémi Longuespée |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1795746793 | ||
| 003 | DE-627 | ||
| 005 | 20230426163652.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220316s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/biomedicines10010001 |2 doi | |
| 035 | |a (DE-627)1795746793 | ||
| 035 | |a (DE-599)KXP1795746793 | ||
| 035 | |a (OCoLC)1341445924 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Fresnais, Margaux |e VerfasserIn |0 (DE-588)1190043157 |0 (DE-627)1668720108 |4 aut | |
| 245 | 1 | 0 | |a Approaching sites of action of temozolomide for pharmacological and clinical studies in glioblastoma |c Margaux Fresnais, Sevin Turcan, Dirk Theile, Johannes Ungermann, Yasmin Abou Zeed, Joshua Raoul Lindner, Marius Breitkopf, Jürgen Burhenne, Walter E. Haefeli and Rémi Longuespée |
| 264 | 1 | |c 2022 | |
| 300 | |a 27 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published: 21 December 2021 | ||
| 500 | |a Gesehen am 16.03.2022 | ||
| 520 | |a Temozolomide (TMZ), together with bulk resection and focal radiotherapy, is currently a standard of care for glioblastoma. Absorption, distribution, metabolism, and excretion (ADME) parameters, together with the mode of action of TMZ, make its biochemical and biological action difficult to understand. Accurate understanding of the mode of action of TMZ and the monitoring of TMZ at its anatomical, cellular, and molecular sites of action (SOAs) would greatly benefit precision medicine and the development of novel therapeutic approaches in combination with TMZ. In the present perspective article, we summarize the known ADME parameters and modes of action of TMZ, and we review the possible methodological options to monitor TMZ at its SOAs. We focus our descriptions of methodologies on mass spectrometry-based approaches, and all related considerations are taken into account regarding the avoidance of artifacts in mass spectrometric analysis during sampling, sample preparation, and the evaluation of results. Finally, we provide an overview of potential applications for precision medicine and drug development. | ||
| 650 | 4 | |a glioblastoma | |
| 650 | 4 | |a omics | |
| 650 | 4 | |a pharmacology | |
| 650 | 4 | |a quantification | |
| 650 | 4 | |a site of action | |
| 650 | 4 | |a temozolomide | |
| 700 | 1 | |a Turcan, S̨evin |e VerfasserIn |0 (DE-588)1167189582 |0 (DE-627)103087414X |0 (DE-576)511022093 |4 aut | |
| 700 | 1 | |a Theile, Dirk |e VerfasserIn |0 (DE-588)1019114428 |0 (DE-627)684195658 |0 (DE-576)356996360 |4 aut | |
| 700 | 1 | |a Ungermann, Johannes |e VerfasserIn |0 (DE-588)1253538425 |0 (DE-627)179575849X |4 aut | |
| 700 | 1 | |a Abou Zeed, Yasmin |e VerfasserIn |0 (DE-588)1253538689 |0 (DE-627)1795758961 |4 aut | |
| 700 | 1 | |a Lindner, Joshua Raoul |e VerfasserIn |0 (DE-588)1253540942 |0 (DE-627)1795768010 |4 aut | |
| 700 | 1 | |a Breitkopf, Marius |e VerfasserIn |0 (DE-588)1253541310 |0 (DE-627)1795768592 |4 aut | |
| 700 | 1 | |a Burhenne, Jürgen |d 1963- |e VerfasserIn |0 (DE-588)1034228889 |0 (DE-627)745126987 |0 (DE-576)381858197 |4 aut | |
| 700 | 1 | |a Haefeli, Walter E. |d 1958- |e VerfasserIn |0 (DE-588)124572359 |0 (DE-627)656806141 |0 (DE-576)340514221 |4 aut | |
| 700 | 1 | |a Longuespée, Rémi |e VerfasserIn |0 (DE-588)113707146X |0 (DE-627)89404690X |0 (DE-576)491093179 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicines |d Basel : MDPI, 2013 |g 10(2022), 1, Artikel-ID 10010001, Seite 1-27 |h Online-Ressource |w (DE-627)750370483 |w (DE-600)2720867-9 |w (DE-576)384589596 |x 2227-9059 |7 nnas |a Approaching sites of action of temozolomide for pharmacological and clinical studies in glioblastoma |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:1 |g elocationid:10010001 |g pages:1-27 |g extent:27 |a Approaching sites of action of temozolomide for pharmacological and clinical studies in glioblastoma |
| 856 | 4 | 0 | |u https://doi.org/10.3390/biomedicines10010001 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2227-9059/10/1/1 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220316 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 113707146X |a Longuespée, Rémi |m 113707146X:Longuespée, Rémi |d 910000 |d 910100 |e 910000PL113707146X |e 910100PL113707146X |k 0/910000/ |k 1/910000/910100/ |p 10 |y j | ||
| 998 | |g 124572359 |a Haefeli, Walter E. |m 124572359:Haefeli, Walter E. |d 910000 |d 910100 |e 910000PH124572359 |e 910100PH124572359 |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 998 | |g 1034228889 |a Burhenne, Jürgen |m 1034228889:Burhenne, Jürgen |d 910000 |d 910100 |e 910000PB1034228889 |e 910100PB1034228889 |k 0/910000/ |k 1/910000/910100/ |p 8 | ||
| 998 | |g 1019114428 |a Theile, Dirk |m 1019114428:Theile, Dirk |d 910000 |d 910100 |d 50000 |e 910000PT1019114428 |e 910100PT1019114428 |e 50000PT1019114428 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 3 | ||
| 998 | |g 1167189582 |a Turcan, S̨evin |m 1167189582:Turcan, S̨evin |d 910000 |d 911100 |e 910000PT1167189582 |e 911100PT1167189582 |k 0/910000/ |k 1/910000/911100/ |p 2 | ||
| 998 | |g 1190043157 |a Fresnais, Margaux |m 1190043157:Fresnais, Margaux |d 910000 |d 910100 |e 910000PF1190043157 |e 910100PF1190043157 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1795746793 |e 4090999200 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Published: 21 December 2021","Gesehen am 16.03.2022"],"person":[{"role":"aut","family":"Fresnais","given":"Margaux","display":"Fresnais, Margaux"},{"family":"Turcan","role":"aut","display":"Turcan, S̨evin","given":"S̨evin"},{"role":"aut","family":"Theile","given":"Dirk","display":"Theile, Dirk"},{"family":"Ungermann","role":"aut","display":"Ungermann, Johannes","given":"Johannes"},{"role":"aut","family":"Abou Zeed","display":"Abou Zeed, Yasmin","given":"Yasmin"},{"given":"Joshua Raoul","display":"Lindner, Joshua Raoul","family":"Lindner","role":"aut"},{"family":"Breitkopf","role":"aut","given":"Marius","display":"Breitkopf, Marius"},{"display":"Burhenne, Jürgen","given":"Jürgen","family":"Burhenne","role":"aut"},{"family":"Haefeli","role":"aut","display":"Haefeli, Walter E.","given":"Walter E."},{"role":"aut","family":"Longuespée","display":"Longuespée, Rémi","given":"Rémi"}],"recId":"1795746793","name":{"displayForm":["Margaux Fresnais, Sevin Turcan, Dirk Theile, Johannes Ungermann, Yasmin Abou Zeed, Joshua Raoul Lindner, Marius Breitkopf, Jürgen Burhenne, Walter E. Haefeli and Rémi Longuespée"]},"language":["eng"],"origin":[{"dateIssuedDisp":"2022","dateIssuedKey":"2022"}],"relHost":[{"disp":"Approaching sites of action of temozolomide for pharmacological and clinical studies in glioblastomaBiomedicines","type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"part":{"year":"2022","volume":"10","extent":"27","pages":"1-27","issue":"1","text":"10(2022), 1, Artikel-ID 10010001, Seite 1-27"},"note":["Gesehen am 12.08.20"],"pubHistory":["1.2013 -"],"title":[{"title":"Biomedicines","subtitle":"open access journal","title_sort":"Biomedicines"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["2227-9059"],"eki":["750370483"],"zdb":["2720867-9"]},"origin":[{"dateIssuedDisp":"2013-","publisher":"MDPI","publisherPlace":"Basel","dateIssuedKey":"2013"}],"recId":"750370483"}],"physDesc":[{"extent":"27 S."}],"id":{"eki":["1795746793"],"doi":["10.3390/biomedicines10010001"]},"title":[{"title_sort":"Approaching sites of action of temozolomide for pharmacological and clinical studies in glioblastoma","title":"Approaching sites of action of temozolomide for pharmacological and clinical studies in glioblastoma"}],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a FRESNAISMAAPPROACHIN2022 | ||